RIGI and leukemia: Treatment of human drug-resistance leukaemia cells with 5′-3P-siRNA-multi-drug resistance 1 (MDR1) down-regulated MDR1 expression and induced RIG-I-dependent immune and pro-apoptotic effects, suggesting a possible synergistic role for 3p-siRNA-MDR1 in anti-leukaemia therapy [61].